EAN 2020 | PREVENT study: eculizumab in patients with AQP4 immunoglobin G-positive NMOSD

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the findings from the Phase III PREVENT study (NCT018923450), a randomized controlled trial assessing the efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).